Cellecta is a contract research company whose primary focus is to develop advanced high-throughput (HT) genetic screen technologies and their applications for the discovery and functional characterization of novel therapeutic targets and drugs. With more than 6 years of experience in the field of HT functional screening with lentiviral shRNA libraries, our scientists have developed the most advanced technology available in collaboration with opinion leaders and with funding from nine NIH SBIR grants.